A positive trend, even if not statistically significant, was also observed in PFS when the targeted agent was earlier used, suggesting that the best place of these agents is probably upfront.
← all excerpts
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
1
—
—